Utilizing mRNA delivery enables transient CAR expression, offering immediate safety control and supporting rapid functional screening. Furthermore, employing gene-editing tools for precise gene knock-in facilitates the development of safer, more universal, and cost-effective CAR-T treatments.
Targeted Drug Delivery for CAR-T Cell Therapy
Chimeric antigen receptor T-cell (CAR-T) therapy achieved revolutionary success in hematologic malignancies, but widespread adoption and breakthroughs in solid tumors face significant challenges in manufacturing efficiency, cost, and product durability. Creative Biolabs' targeted delivery technology focuses on providing next-generation, non-viral genetic engineering solutions to optimize CAR-T manufacturing processes and dramatically improve their clinical performance.
What is Targeted Delivery in CAR-T?
Targeted delivery here specifically refers to the efficient, precise, and low-toxicity introduction of the CAR-encoding gene (DNA or mRNA) directly into a patient's T cells, whether in vivo or ex vivo. This concept extends beyond simple delivery to functional augmentation. Key aspects include Efficiency, ensuring a high percentage of T cells are successfully modified without extensive cell culture; Safety, by utilizing non-viral vectors to avoid the potential tumorigenic risk of random genomic integration; and Precision, enabling functional genes to be co-delivered to overcome the immunosuppressive tumor microenvironment (TME) and enhance T-cell persistence.
Next-Generation Applications for CAR-T Cell Therapy
Advanced delivery technologies are fundamentally shaping the fifth generation of CAR-T therapeutics:
Development of Non-Viral CAR-T Products
Solid Tumor CAR-T Optimization
The ability to precisely deliver additional functional genes, such as activating cytokines and homing chemokine receptors, significantly enhances both tumor-site infiltration and the in vivo persistence and metabolic resilience of CAR-T cells.
Multi-Target/Safety Switch Design
High-fidelity delivery systems facilitate the integration of complex genetic payloads, supporting the design of dual-target CARs to overcome antigen escape, or the incorporation of suicide genes/safety switches to improve CAR-T specificity and ensure controlled in vivo safety.
Fig.1 Intracellular process of lipid nanoparticle (LNP) as a carrier for transporting CAR cargo.1
Delivery Challenges of Traditional CAR-T Engineering
The bottlenecks in first and second-generation CAR-T production stem from outdated delivery methodologies:
Viral Vector Limitations Transduction Efficiency and Cell Viability Safety and Random Integration In vivo Persistence and CAR-T Depletion
Traditional lentiviral and retroviral vectors are inherently expensive, require complex and time-consuming BSL-2 manufacturing, and are subject to limited, inflexible supply chains that slow down clinical development.
What We Can Offer
Creative Biolabs provides professional, industry-leading non-viral delivery technologies and process optimization services engineered to solve the pain points of CAR-T manufacturing and clinical translation:
High-Efficiency Non-Viral CAR Delivery
We offer optimized LNP/polymer nanoparticles specifically designed for T cells. Our platforms achieve high transfection efficiency while eliminating the potential genotoxic risk of random insertion associated with traditional viral vectors, paving the way for in vivo CAR-T treatments.
mRNA CAR Platform Support
We provide customized non-viral vectors for CAR-mRNA encapsulation and rapid transfection, supporting the quick screening, development, and manufacturing of transiently expressed CAR-T cells for enhanced safety and flexibility.
Functional Gene Co-delivery
Our nanosystems are engineered to co-encapsulate CAR genes alongside functional regulatory molecules (such as cytokine mRNA or immune checkpoint inhibitor siRNA) to comprehensively and locally enhance the anti-tumor activity and in vivo persistence of CAR-T.
Process Scale-up and Automation Integration
Our non-viral delivery solutions offer superior batch stability and simplified, scalable protocols, seamlessly integrating into automated cell manufacturing platforms. This dramatically reduces production costs and cycle times, accelerating your path to the clinic.
Why Choose Us?
Validated Expertise
Our platforms are grounded in leading scientific consensus on non-viral gene delivery.
Safety Profile
Eliminate random integration risk with our specialized non-viral vectors.
Scalability
Achieve superior batch stability and automated manufacturing integration.
Functional Enhancement
Proprietary technology for localized cytokine boosting and TME modulation.
Workflow
Whether you are optimizing existing ex vivo processes or developing next-generation non-viral CAR-T products, our team of targeted delivery experts can provide customized, strategic support. Please contact us to accelerate your CAR-T therapy journey and achieve precision in oncology.
Reference
- Cao, Lili, Yingying Liu, and Guimei Lin. "Strategies for Altering Delivery Technologies to Optimize CAR Therapy." International Journal of Molecular Sciences 26.7 (2025): 3206. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms26073206.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
